Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Advanced Course on Early Drug Development 2024: Hong Kong SAR, China
- Start date
- 02 Feb 2024
- End date
- 04 Feb 2024
- Location
- Hong Kong SAR, China
Learning objectives
- To foster, educate and mentor the next generation of Phase I/Early Drug Development Programmes in Oncology centres from both the established and emerging economies in the Asia-Pacific region.
- To understand the fundamentals to establishing and running a successful Phase I/Early Drug Development Programme: from an in-depth understanding of trial selection to patient coordination, to running a programme, to effectively engaging with sponsors and fellow PIs, regional and international engagement, regulatory processes.
- To bridge the gap between the key stakeholders in the drug development process in the Asia-Pacific region: investigators, sponsors (Pharma and Biotech), Contract Research Organization (CRO), regulatory bodies.
Accreditation
The programme of this event has been accredited with 15 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Co-Chairs
- Jayesh Desai, Australia
- Elena Garralda, Spain
- Brigette Ma, Hong Kong SAR, China
Supported by
